secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2024-09-10T23:59:59+00:00
Accession:  0001140361-24-040650
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant unveils mosliciguat, inhaled sGC activator for PH-ILD; Phase 1b shows PVR reduction up to 38%
--------------------------------------------------------------------------------

- Phase 1b ATMOS in 38 PH patients: single dose of mosliciguat produced mean-max PVR reduction up to ~38%, exceeding ≥20% threshold.
- Mosliciguat is potential first-in-class, inhaled once-daily sGC activator with targeted lung delivery via dry powder inhaler.
- Global Phase 2 PHocus study in ~120 PH-ILD patients imminent; PH-ILD prevalence ~200,000 in US/Europe with few treatments.
- Roivant in-licensed from Bayer for ~$14M upfront, up to $280M milestones + tiered high-single digit royalties.
- Favorable safety in 170 participants; 40-hour half-life enables once-daily dosing; differentiated from existing therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124040650/0001140361-24-040650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124040650/ef20035693_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-040650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer